Skip to Content

Hengrui, which made $2.5 billion in sales last year, invests twice as much as any other pharma in R&D, and its investments are paying off: It’s China’s largest pharmaceutical company and a leader in innovation. China’s plan to bulk-purchase generic drugs in 2020 will drive down industry prices, but analysts say only 1% to 2% of Jiangsu’s revenue will be impacted, while competitors in its peer group will be more exposed.

Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

Company Information

Overall Score2.1
Sector
Health Care
Industry
Pharmaceuticals
CEO
Sun Piaoyang
Websitehttps://www.hrs.com.cn
HQ Location
Lianyungang, China
Country
China
Revenues ($M) (Past 12 Months)$2,884
Profits ($M) (Past 12 Months)$669
Market Value as of Oct. 9, 2019 ($M)$48,796
Employees21,016

Refinitiv Sustainable Leadership Monitor

placeholder